Category: Prostate Cancer Diagnosis

A 490-man trial found that a shorter prostate MRI matched the longer version almost exactly at detecting significant cancer. That result is pushing health systems worldwide toward the faster scan. Yet certain cases still hinge on the contrast sequence the shortcut leaves out, including ambiguous PI-RADS 3 lesions and small Gleason 7 tumors. keep reading

What makes one prostate biopsy better than another? It often comes down to two things: how clearly the doctor can see the target, and how many needles it takes to reach it. Real-time MRI guidance can pinpoint a suspicious lesion with just a few samples, while older methods rely on more needles and more guesswork. Accuracy and safety both hang on that choice. keep reading

A prostate MRI can detect cancer without contrast but how confident can a doctor be? DCE-MRI adds a third layer of information by capturing tumor blood flow patterns that plain MRI can't show. Gadolinium makes this possible, and modern formulations have an impressive safety record: over 170 million doses studied. keep reading

Prostate cancer once looked simple. It isn't. Science now knows there are at least 15 distinct cell lines, a single tumor can harbor multiple, and each patient's cancer behaves differently. Genomic biomarker tests are changing how doctors navigate that complexity, defining risk more precisely and helping tailor treatment to the individual. keep reading

The Sperling Prostate Center combines advanced 3T mpMRI technology with artificial intelligence for unmatched accuracy in diagnosing prostate cancer. Dr. Dan Sperling and his team use these tools to determine who truly needs a biopsy and who can safely avoid it, helping men receive highly personalized and effective care. keep reading

Researchers are questioning if PSMA-PET scans, usually reserved for advanced prostate cancer, might offer added value when used alongside mpMRI earlier in diagnosis. Studies suggest a combined approach could improve detection, but questions remain about cost, accuracy, and future role. keep reading

What happens when cutting-edge MRI isn’t within reach for prostate cancer screening? A simple blood test now promises to cut needless biopsies and healthcare costs. The Stockholm3 test combines genetic, protein, and clinical markers to fine-tune prostate cancer detection—potentially sparing men invasive procedures. keep reading

A groundbreaking study reveals how artificial intelligence outperforms traditional methods in prostate cancer risk stratification. By leveraging deep learning and digital biopsy data, AI enhances accuracy, reduces errors, and improves treatment planning for better outcomes. Learn how this innovative technology is transforming prostate cancer diagnosis and care. keep reading

Want to avoid a biopsy after an abnormal PSA test? A new study shows that a negative multiparametric MRI might just be your ticket. Learn how MRI scans are reducing unnecessary biopsies and pinpointing significant prostate cancer with precision. keep reading

The debate continues: is Gleason 6 prostate cancer truly cancer, or is it something else entirely? Discover the ongoing controversy over terminology, patient outcomes, and what the latest research suggests about the risks of overdiagnosis and overtreatment. keep reading